Biotechnology · Healthcare
Eric Warren
Analyst
Sales Team Representative
Equibles does not estimate personal net worth.
About Eric Warren
Eric Warren is recorded as Analyst at Sales Team Representative. The proxy statement of Esperion Therapeutics, Inc. reports total compensation of $1,149,844 for Eric Warren in fiscal 2024, including a base salary of $481,867. Disclosed compensation is on record for 2 fiscal years. Eric Warren has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Mineralys Therapeutics, Inc. on September 9, 2026. Mineralys Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Mineralys Therapeutics, Inc. includes Jon Congleton (CEO and Board Member), Glenn P. Sblendorio (Chairman), Alexander Gold (Board Member) and 7 others.
Eric Warren on recent calls
“Yeah, so gaining experience in fourth line is a natural kind of predictor of increased third line utilization. Guidelines very well could play a role in that as well.”
“Approximately 20 million adults in the United States have uncontrolled or resistant hypertension, and despite the availability of numerous antihypertensive therapies, these patients remain unable to achieve their blood pressure goal.”
“So it's all about sequencing, Richard, so that fourth line is the entry point. But obviously, there is a need for those comorbid patients that are third-line patients.”
“Yeah, and Jason, I'm just back from a large payer conference in Orlando, PCMA, where the team was engaging Medicare as well as commercial payers. I will say we're on their radar.”
“I'll just add that the definition of goal was different when looking at the Bax24 data, where they used a more lenient definition. We used a more stringent definition.”
Affiliation history
-
Sales Team Representative
Analyst
Source not stated
Current -
Mineralys Therapeutics, Inc. (MLYS)
Source not stated
Current -
Esperion Therapeutics, Inc.
Proxy statement
Start not stated–2025-04-18
Company network
Esperion Therapeutics, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare
Leadership on record at Mineralys Therapeutics, Inc.
- Jon Congleton CEO, Board Member
- Glenn P. Sblendorio Chairman
- Alexander Gold Board Member
- Alexander M. Gold, M.D. Board Member
- Brian Taylor Slingsby Board Member
- Daphne Karydas Board Member
- Derek DiRocco Board Member
- Kristine Peterson Board Member
- Lonnel Coats Board Member
- Srinivas Akkaraju Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Esperion Therapeutics, Inc. | Chief Commercial Officer | $481,867 | $1,149,844 |
| 2023 | Esperion Therapeutics, Inc. | Chief Commercial Officer | $462,500 | $1,077,705 |